Hurler Syndrome
Conditions
Keywords
Hurler Syndrome, mucopolysaccharidosis type I, Iduronidase deficiency
Brief summary
This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoing transplantation.
Detailed description
Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture (also called a spinal tap).
Interventions
DRUGIRT Laronidase
Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup. Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture
Sponsors
Masonic Cancer Center, University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 3 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of MPS IH (Hurler syndrome) are candidates for this protocol if they are being considered for hematopoietic stem cell transplantation according the University of Minnesota guidelines.
Exclusion criteria
* Patients are less than 6 months old, or older than 3 years of age. * There is a history of clinically-severe hypersensitivity to Laronidase. * There is a contraindication for repeated lumbar puncture. * The family is not willing to undergo the necessary procedures and evaluations inherent in the study. * Consent has not been signed for participation in the 2004-09 study of intravenous Laronidase administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To demonstrate the efficacy of intrathecally delivering alpha-L-iduronidase in patients with mucopolysaccharidosis type I in decreasing neurodevelopmental deterioration | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| To determine the safety and toxicity of intrathecally delivering alpha-L-iduronidase in patients with mucopolysaccharidosis type I | 1 year |
| To determine brain changes with magnetic resonance imaging | 1 and 2 years |
| To determine neurocognitive changes present in patients with Hurler syndrome | 6, 12, and 24 months |
| To determine cerebral spinal fluid levels of glycosaminoglycans, cytokines and antibodies to Laronidase at baseline and at each point CSF is obtained | through 1 year |
Countries
United States
Outcome results
None listed